Peptide ligands of the urokinase receptor
AssigneesChiron Corporation, Brigham and Women's Hospital Harvard Medical School
InventorsSteven Rosenberg, Michael V. Doyle, Harold A. Chapman
Life of this patent
Estimating the term…
Abstract
Novel peptides that are capable of binding to uPAR and inhibiting the binding of an integrin and vitronectin are described. Also provided are nucleic acid sequences encoding the novel peptides. Methods for screening for small molecules, other peptides, or peptoids that mimic the antagonistic function of the peptides of the invention are described. The invention has applications in design of therapeutics for treating disorders characterized by upregulation of uPA and uPAR, and cancer and chronic inflammation, cell migration or uPAR: integrin binding interactions, and diagnostical applications to such disorders.
Claims4
An isolated peptide that binds a urokinase plasnminogen activator receptor (uPAR) and inhibits uPAR binding to vitronectin, wherein the isolated peptide comprises an amino acid sequence selected from the group consisting of AEPVYQYELDSYLRSYY (SEQ ID NO:1), and AELDLSTFYDIQYLLRT (SEQ ID NO:
- 3).
An isolated peptide that binds a urokinase plasminogen activator receptor (uPAR), comprising an amino acid sequence selected from the group consisting of AEFFKLGPNGYVYLHSA (SEQ ID NO:2) and FKLXXXGYVL (SEQ ID NO:6 where X is any amino acid.
A pharmaceutical composition for treating a patient with a disorder characterized by upregulation of uPA and uPAR comprising an effective amount of a peptide that comprises an amino acid sequence selected from the group consisting of AEPVYQYELDSYLRSYY (SEQ ID NO:
- 1), AEFFKLGPNGYVYLHSA (SEQ ID NO:2), AELDLSTFYDIQYLLRT (SEQ ID NO:3), and FKLXXXGYVYL (SEQ ID NO:6), where X is any amino acid.
Dependencies are inferred from the claim text.